<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ULTRACET- tramadol hydrochloride and acetaminophen tablet, coated </strong><br>Janssen Pharmaceuticals, Inc.<br></p></div>
<h1>ULTRACET<span class="Sup">®</span> C IV<br> (tramadol hydrochloride/acetaminophen)<br> Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">HEPATOTOXICITY</span></h1>
<p class="First"><span class="Bold">ULTRACET<span class="Sup">®</span> contains tramadol HCl and acetaminophen. Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product (see<a href="#warnings"> WARNINGS</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ULTRACET<span class="Sup">®</span> (tramadol hydrochloride/acetaminophen) Tablets combines two analgesics, tramadol 37.5 mg and acetaminophen 325 mg.</p>
<p>The chemical name for tramadol hydrochloride is (±)<span class="Italics">cis</span>-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d20df3c-8b5b-4bdf-a49f-ec904522575d&amp;name=ultracet-01.jpg"></div>
<p>The molecular weight of tramadol hydrochloride is 299.84. Tramadol hydrochloride is a white, bitter, crystalline, and odorless powder.</p>
<p>The chemical name for acetaminophen is <span class="Italics">N</span>-acetyl-<span class="Italics">p</span>-aminophenol. Its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d20df3c-8b5b-4bdf-a49f-ec904522575d&amp;name=ultracet-02.jpg"></div>
<p>The molecular weight of acetaminophen is 151.17. Acetaminophen is an analgesic and antipyretic agent which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste.</p>
<p>ULTRACET<span class="Sup">®</span> tablets contain 37.5 mg tramadol hydrochloride and 325 mg acetaminophen and are light yellow in color. Inactive ingredients in the tablet are powdered cellulose, pregelatinized corn starch, sodium starch glycolate, corn starch, magnesium stearate, hypromellose, polyethylene glycol, polysorbate 80, titanium dioxide, iron oxide, and carnauba wax.</p>
<p>Meets USP Dissolution Test 2</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The following information is based on studies of tramadol alone or acetaminophen alone, except where otherwise noted:</p>
<div class="Section" data-sectionCode="43681-6">
<a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">ULTRACET<span class="Sup">®</span> contains tramadol and acetaminophen. Tramadol is a centrally acting synthetic opioid analgesic. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to µ-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin.</p>
<p>Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and 200 times more potent in µ-opioid binding. Tramadol-induced <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is only partially antagonized by the opiate antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is dependent upon the plasma concentrations of each compound (see<span class="Bold"><a href="#pharmacokinetics"> CLINICAL PHARMACOLOGY, Pharmacokinetics</a></span>).</p>
<p>Tramadol has been shown to inhibit reuptake of norepinephrine and serotonin<span class="Italics"> in vitro, </span>as have some other opioid analgesics. These mechanisms may contribute independently to the overall analgesic profile of tramadol.</p>
<p>Apart from <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, tramadol administration may produce a constellation of symptoms (including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) similar to that of other opioids.</p>
<p>Acetaminophen is a non-opiate, non-salicylate analgesic.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="pharmacokinetics"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Tramadol is administered as a racemate and both the [-] and [+] forms of both tramadol and M1 are detected in the circulation. The pharmacokinetics of plasma tramadol and acetaminophen following oral administration of one ULTRACET<span class="Sup">®</span> tablet are shown in Table 1. Tramadol has a slower absorption and longer half-life when compared to acetaminophen.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Summary of Mean (±SD) Pharmacokinetic Parameters of the (+)- and (-) Enantiomers of Tramadol and M1 and Acetaminophen Following A Single Oral Dose Of One Tramadol/Acetaminophen Combination Tablet (37.5 mg/325 mg) in Volunteers</span></caption>
<col align="left" valign="top" width="15%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<thead><tr class="First Last">
<th align="left">Parameter<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="center" colspan="2">(+)-Tramadol</th>
<th align="center" colspan="2">(-)-Tramadol</th>
<th align="center" colspan="2">(+)-M1</th>
<th align="center" colspan="2">(-)-M1</th>
<th align="center" colspan="2">acetaminophen</th>
</tr></thead>
<tfoot><tr><td colspan="11" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>For acetaminophen, C<span class="Sub">max</span> was measured as µg/mL.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">C<span class="Sub">max</span> (ng/mL)</td>
<td align="center">64.3</td>
<td align="center">(9.3)</td>
<td align="center">55.5</td>
<td align="center">(8.1)</td>
<td align="center">10.9</td>
<td align="center">(5.7)</td>
<td align="center">12.8</td>
<td align="center">(4.2)</td>
<td align="center">4.2</td>
<td align="center">(0.8)</td>
</tr>
<tr>
<td align="left">t<span class="Sub">max</span> (h)</td>
<td align="center">1.8</td>
<td align="center">(0.6)</td>
<td align="center">1.8</td>
<td align="center">(0.7)</td>
<td align="center">2.1</td>
<td align="center">(0.7)</td>
<td align="center">2.2</td>
<td align="center">(0.7)</td>
<td align="center">0.9</td>
<td align="center">(0.7)</td>
</tr>
<tr>
<td align="left">CL/F (mL/min)</td>
<td align="center">588</td>
<td align="center">(226)</td>
<td align="center">736</td>
<td align="center">(244)</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">365</td>
<td align="center">(84)</td>
</tr>
<tr class="Last">
<td align="left">t<span class="Sub">1/2</span> (h)</td>
<td align="center">5.1</td>
<td align="center">(1.4)</td>
<td align="center">4.7</td>
<td align="center">(1.2)</td>
<td align="center">7.8</td>
<td align="center">(3.0)</td>
<td align="center">6.2</td>
<td align="center">(1.6)</td>
<td align="center">2.5</td>
<td align="center">(0.6)</td>
</tr>
</tbody>
</table>
<p>A single-dose pharmacokinetic study of ULTRACET<span class="Sup">®</span> in volunteers showed no drug interactions between tramadol and acetaminophen. Upon multiple oral dosing to steady state, however, the bioavailability of tramadol and metabolite M1 was lower for the combination tablets compared to tramadol administered alone. The decrease in AUC was 14% for (+)-tramadol, 10.4% for (-)-tramadol, 11.9% for (+)-M1, and 24.2% for (-)-M1. The cause of this reduced bioavailability is not clear. Following single- or multiple-dose administration of ULTRACET<span class="Sup">®</span>, no significant change in acetaminophen pharmacokinetics was observed when compared to acetaminophen given alone.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">The absolute bioavailability of tramadol from ULTRACET<span class="Sup">®</span> tablets has not been determined. Tramadol hydrochloride has a mean absolute bioavailability of approximately 75% following administration of a single 100 mg oral dose of ULTRAM<span class="Sup">®</span> tablets. The mean peak plasma concentration of racemic tramadol and M1 after administration of two ULTRACET<span class="Sup">®</span> tablets occurs at approximately two and three hours, respectively, post-dose.</p>
<p>Peak plasma concentrations of acetaminophen occur within one hour and are not affected by co-administration with tramadol. Oral absorption of acetaminophen following administration of ULTRACET<span class="Sup">®</span> occurs primarily in the small intestine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3>Food Effects</h3>
<p class="First">When ULTRACET<span class="Sup">®</span> was administered with food, the time to peak plasma concentration was delayed for approximately 35 minutes for tramadol and almost one hour for acetaminophen. However, peak plasma concentrations, and the extents of absorption, of tramadol and acetaminophen were not affected. The clinical significance of this difference is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<h3>Distribution</h3>
<p class="First">The volume of distribution of tramadol was 2.6 and 2.9 L/kg in male and female subjects, respectively, following a 100 mg intravenous dose. The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 µg/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range.</p>
<p>Acetaminophen appears to be widely distributed throughout most body tissues except fat. Its apparent volume of distribution is about 0.9 L/kg. A relative small portion (~20%) of acetaminophen is bound to plasma protein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Following oral administration, tramadol is extensively metabolized by a number of pathways, including CYP2D6 and CYP3A4, as well as by conjugation of parent and metabolites. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The major metabolic pathways appear to be <span class="Italics">N</span>- and <span class="Italics">O</span>-demethylation and glucuronidation or sulfation in the liver. Metabolite M1 (<span class="Italics">O</span>-desmethyltramadol) is pharmacologically active in animal models. Formation of M1 is dependent on CYP2D6 and as such is subject to inhibition, which may affect the therapeutic response (see<span class="Bold"><a href="#DI"> PRECAUTIONS, Drug Interactions</a></span>).</p>
<p>Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P450. These individuals are "poor metabolizers" of debrisoquine, dextromethorphan, and tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase 1 studies in healthy subjects, concentrations of tramadol were approximately 20% higher in "poor metabolizers" versus "extensive metabolizers," while M1 concentrations were 40% lower.<span class="Italics"> In vitro </span>drug interaction studies in human liver microsomes indicate that inhibitors of CYP2D6 such as fluoxetine and its metabolite norfluoxetine, amitriptyline, and quinidine inhibit the metabolism of tramadol to various degrees. The full pharmacological impact of these alterations in terms of either efficacy or safety is unknown. Concomitant use of SEROTONIN re-uptake INHIBITORS and MAO INHIBITORS may enhance the risk of adverse events, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (see<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>) and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
<p>Acetaminophen is primarily metabolized in the liver by first-order kinetics and involves three principal separate pathways:</p>
<dl>
<dt>a)</dt>
<dd>conjugation with glucuronide;</dd>
<dt>b)</dt>
<dd>conjugation with sulfate; and</dd>
<dt>c)</dt>
<dd>oxidation via the cytochrome, P450-dependent, mixed-function oxidase enzyme pathway to form a reactive intermediate metabolite, which conjugates with glutathione and is then further metabolized to form cysteine and mercapturic acid conjugates. The principal cytochrome P450 isoenzyme involved appears to be CYP2E1, with CYP1A2 and CYP3A4 as additional pathways.</dd>
</dl>
<p>In adults, the majority of acetaminophen is conjugated with glucuronic acid and, to a lesser extent, with sulfate. These glucuronide-, sulfate-, and glutathione-derived metabolites lack biologic activity. In premature infants, newborns, and young infants, the sulfate conjugate predominates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5"></a><p></p>
<h3>Elimination</h3>
<p class="First">Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. The plasma elimination half-lives of racemic tramadol and M1 are approximately 5–6 and 7 hours, respectively, after administration of ULTRACET<span class="Sup">®</span>. The apparent plasma elimination half-life of racemic tramadol increased to 7–9 hours upon multiple dosing of ULTRACET<span class="Sup">®</span>.</p>
<p>The half-life of acetaminophen is about 2 to 3 hours in adults. It is somewhat shorter in children and somewhat longer in neonates and in cirrhotic patients. Acetaminophen is eliminated from the body primarily by formation of glucuronide and sulfate conjugates in a dose-dependent manner. Less than 9% of acetaminophen is excreted unchanged in the urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<h3>Renal</h3>
<p class="First">The pharmacokinetics of ULTRACET<span class="Sup">®</span> in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has not been studied. Based on studies using tramadol alone, excretion of tramadol and metabolite M1 is reduced in patients with creatinine clearance of less than 30 mL/min. Adjustment of dosing regimen in this patient population is recommended (see<span class="Bold"><a href="#DAA"> DOSAGE AND ADMINISTRATION</a></span>). The total amount of tramadol and M1 removed during a 4-hour dialysis period is less than 7% of the administered dose based on studies using tramadol alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<h3>Hepatic</h3>
<p class="First">The pharmacokinetics and tolerability of ULTRACET<span class="Sup">®</span> in patients with impaired hepatic function have not been studied. Since tramadol and acetaminophen are both extensively metabolized by the liver, the use of ULTRACET<span class="Sup">®</span> in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not recommended (see<span class="Bold"><a href="#precautions"> PRECAUTIONS </a></span>and<span class="Bold"><a href="#DAA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.3"></a><p></p>
<h3>Geriatric</h3>
<p class="First">A population pharmacokinetic analysis of data obtained from a clinical trial in patients with <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> treated with ULTRACET<span class="Sup">®</span>, which included 55 patients between 65 and 75 years of age and 19 patients over 75 years of age, showed no significant changes in the pharmacokinetics of tramadol and acetaminophen in elderly patients with normal renal and hepatic function (see<span class="Bold"><a href="#geriatric"> PRECAUTIONS, Geriatric Use</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.4"></a><p></p>
<h3>Gender</h3>
<p class="First">Tramadol clearance was 20% higher in female subjects compared to males on four phase I studies of ULTRACET<span class="Sup">®</span> in 50 male and 34 female healthy subjects. The clinical significance of this difference is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.5"></a><p></p>
<h3>Pediatric</h3>
<p class="First">The pharmacokinetics of ULTRACET<span class="Sup">®</span> tablets has not been studied in pediatric patients below 16 years of age.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CS"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Single-Dose Studies for Treatment of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">Acute Pain</span></h2>
<p class="First">In pivotal single-dose studies in <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>, two tablets of ULTRACET<span class="Sup">®</span> administered to patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following oral surgical procedures provided greater relief than placebo or either of the individual components given at the same dose. The onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief after ULTRACET<span class="Sup">®</span> was faster than tramadol alone. Onset of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> occurred in less than one hour. The duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief after ULTRACET<span class="Sup">®</span> was longer than acetaminophen alone. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> was generally comparable to that of the comparator, ibuprofen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ULTRACET<span class="Sup">®</span> is indicated for the short-term (five days or less) management of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ULTRACET<span class="Sup">®</span> should not be administered to patients who have previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tramadol, acetaminophen, any other component of this product, or opioids. ULTRACET<span class="Sup">®</span> is contraindicated in any situation where opioids are contraindicated, including acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with any of the following: alcohol, hypnotics, narcotics, centrally acting analgesics, opioids, or psychotropic drugs. ULTRACET<span class="Sup">®</span> may worsen central nervous system and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First"><span class="Bold">ULTRACET<span class="Sup">®</span> contains tramadol HCl and acetaminophen. Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief or unknowingly take other acetaminophen-containing products (see<a href="#BOX"> Boxed Warning</a>).</span></p>
<p><span class="Bold">The risk of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.</span></p>
<p><span class="Bold">Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4,000 milligrams of acetaminophen per day, even if they feel well.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">Rarely, acetaminophen may cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span> (<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">AGEP</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. Patients should be informed about the signs of serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="warning_SR"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Risk</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in patients receiving tramadol within the recommended dosage range. Spontaneous post-marketing reports indicate that <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk is increased with doses of tramadol above the recommended range. Concomitant use of tramadol increases the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk in patients taking:</span></p>
<ul class="Disc">
<li><span class="Bold">Selective serotonin reuptake inhibitors (SSRI antidepressants or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectics</span>),</span></li>
<li><span class="Bold">Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or</span></li>
<li><span class="Bold">Other opioids.</span></li>
</ul>
<p><span class="Bold">Administration of tramadol may enhance the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk in patients taking:</span></p>
<ul class="Disc">
<li><span class="Bold">MAO inhibitors (see also<a href="#uwmiasrui"> WARNINGS, Use with MAO Inhibitors and Serotonin Re-uptake Inhibitors</a>),</span></li>
<li><span class="Bold">Neuroleptics, or</span></li>
<li><span class="Bold">Other drugs that reduce the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</span></li>
</ul>
<p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> may also increase in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, those with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or in patients with a recognized risk for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (such as head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>, alcohol and drug withdrawal, or CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>). In tramadol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, naloxone administration may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<ul class="Disc">
<li><span class="Bold">Do not prescribe ULTRACET<span class="Sup">®</span> for patients who are suicidal or addiction-prone.</span></li>
<li>
<span class="Bold">Prescribe ULTRACET</span><span class="Sup">®</span><span class="Bold"> with caution for patients taking tranquilizers or antidepressant drugs and patients who use alcohol in excess and who suffer from <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbance</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</span>
</li>
</ul>
<p class="First">The judicious prescribing of tramadol is essential to the safe use of this drug. With patients who are depressed or suicidal, consideration should be given to the use of non-narcotic analgesics.</p>
<p>Tramadol-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred in patients with previous histories of <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> or attempts as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs (see<span class="Bold"><a href="#ROO"> WARNINGS, Risk of Overdosage</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="war_SS"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</h2>
<p class="First"><span class="Bold">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur with the use of tramadol products, including ULTRACET</span><span class="Sup">®</span><span class="Bold">, particularly with concomitant use of serotonergic drugs such as SSRIs, SNRIs, TCAs, MAOIs, and triptans, with drugs which impair metabolism of serotonin (including MAOIs), and with drugs which impair metabolism of tramadol (CYP2D6 and CYP3A4 inhibitors). This may occur within the recommended dose (see<a href="#pharmacokinetics"> CLINICAL PHARMACOLOGY, Pharmacokinetics</a>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may include mental-status changes (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">Serious and rarely fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients receiving therapy with tramadol. When these events do occur it is often following the first dose. Other reported <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. Patients with a history of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> to codeine and other opioids may be at increased risk and therefore should not receive ULTRACET<span class="Sup">®</span> (see<span class="Bold"><a href="#contraindications"> CONTRAINDICATIONS</a></span>).</p>
<p>There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> associated with the use of acetaminophen. Clinical signs included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth, and throat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. There were infrequent reports of life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> requiring emergency medical attention. Instruct patients to discontinue ULTRACET<span class="Sup">®</span> immediately and seek medical care if they experience these symptoms. Do not prescribe ULTRACET<span class="Sup">®</span> for patients with acetaminophen <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="warning_RD"></a><a name="section-6.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Administer ULTRACET<span class="Sup">®</span> cautiously in patients at risk for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In these patients, alternative non-opioid analgesics should be considered. When large doses of tramadol are administered with anesthetic medications or alcohol, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may result. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> should be treated as an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. If naloxone is to be administered, use cautiously because it may precipitate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (see<span class="Bold"><a href="#warning_SR"> WARNINGS, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Risk </a></span>and<span class="Bold"><a href="#OD"> OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8"></a><p></p>
<h2>Interaction With Central Nervous System (CNS) Depressants</h2>
<p class="First">ULTRACET<span class="Sup">®</span> should be used with caution and in reduced dosages when administered to patients receiving CNS depressants such as alcohol, opioids, anesthetic agents, narcotics, phenothiazines, tranquilizers, or sedative hypnotics. Tramadol increases the risk of CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.9"></a><p></p>
<h2>Interactions With Alcohol and Drugs of Abuse</h2>
<p class="First">Tramadol may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> or Head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></h2>
<p class="First">ULTRACET<span class="Sup">®</span> should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>. The respiratory depressant effects of opioids include <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention and secondary elevation of cerebrospinal fluid pressure and may be markedly exaggerated in these patients. Additionally, pupillary changes (<span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>) from tramadol may obscure the existence, extent, or course of intracranial pathology. Clinicians should also maintain a high index of suspicion for adverse drug reactions when evaluating altered mental status in these patients if they are receiving ULTRACET<span class="Sup">®</span> (see<span class="Bold"><a href="#warning_RD"> WARNINGS, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.11"></a><p></p>
<h2>Use in Ambulatory Patients</h2>
<p class="First">Tramadol may impair the mental and or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="uwmiasrui"></a><a name="section-6.12"></a><p></p>
<h2>Use With MAO Inhibitors and Serotonin Re-uptake Inhibitors</h2>
<p class="First">Use ULTRACET<span class="Sup">®</span> with great caution in patients taking monoamine oxidase inhibitors. Animal studies have shown increased <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> with combined administration of MAO inhibitors and tramadol. Concomitant use of tramadol with MAO inhibitors or SSRIs increases the risk of adverse events, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="uwa"></a><a name="section-6.13"></a><p></p>
<h2>Use With Alcohol</h2>
<p class="First">ULTRACET<span class="Sup">®</span> should not be used concomitantly with alcohol consumption. The use of ULTRACET<span class="Sup">®</span> in patients with liver disease is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="uwoacp"></a><a name="section-6.14"></a><p></p>
<h2>Use With Other Acetaminophen-containing Products</h2>
<p class="First">Due to the potential for acetaminophen hepatotoxicity at doses higher than the recommended dose, ULTRACET<span class="Sup">®</span> should not be used concomitantly with other acetaminophen-containing products.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="war_maad"></a><a name="section-6.15"></a><p></p>
<h2>Misuse, Abuse and Diversion</h2>
<p class="First">Tramadol has mu-opioid agonist activity. ULTRACET<span class="Sup">®</span>, a tramadol-containing product, can be sought by drug abusers and people with addiction disorders and may be subject to criminal diversion. The possibility of illegal or illicit use should be considered when prescribing or dispensing ULTRACET<span class="Sup">®</span> in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Misuse or abuse poses a significant risk to the abuser that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see<span class="Bold"><a href="#DAAD"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </a></span>and<span class="Bold"><a href="#OD"> OVERDOSAGE</a></span>).</p>
<p>Concerns about abuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The development of addiction to opioid analgesics in properly managed patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> has been reported to be rare. However, data are not available to establish the true incidence of addiction in <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="roo"></a><a name="section-6.16"></a><p></p>
<h2>Risk of Overdosage</h2>
<p class="First">Patients taking tramadol should be warned not to exceed the dose recommended by their physician. Tramadol products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a cause of drug-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Patients should be cautioned about the concomitant use of tramadol products and alcohol because of potentially serious CNS additive effects of these agents. Because of its added depressant effects, tramadol should be prescribed with caution for those patients whose medical condition requires the concomitant administration of sedatives, tranquilizers, muscle relaxants, tricyclic antidepressants, or other CNS depressant drugs. Patients should be advised of the additive depressant effects of these combinations.</p>
<p>Serious potential consequences of overdosage with tramadol are central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred as a consequence of the accidental ingestion of excessive quantities of tramadol alone or in combination with other drugs. In treating an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, primary attention should be given to maintaining adequate ventilation along with general supportive treatment (see<span class="Bold"><a href="#OD"> OVERDOSAGE</a></span>).</p>
<p>A serious potential consequence of overdosage with acetaminophen is hepatic (centrilobular) <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, leading to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Emergency help should be sought immediately and treatment initiated immediately if <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is suspected, even if symptoms are not apparent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="war_withdrawal"></a><a name="section-6.17"></a><p></p>
<h2>Withdrawal</h2>
<p class="First">Withdrawal symptoms may occur if ULTRACET<span class="Sup">®</span> is discontinued abruptly (see also<span class="Bold"><a href="#DAAD"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>). Reported symptoms have included <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, upper respiratory symptoms, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, and rarely <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Other symptoms that have been reported less frequently with ULTRACET<span class="Sup">®</span> discontinuation include: <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, severe <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>. Clinical experience suggests that withdrawal symptoms may be avoided by tapering ULTRACET<span class="Sup">®</span> at the time of discontinuation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The recommended dose of ULTRACET<span class="Sup">®</span> should not be exceeded.</p>
<p>Do not co-administer ULTRACET<span class="Sup">®</span> with other tramadol or acetaminophen-containing products (see<span class="Bold"><a href="#uwoacp"> WARNINGS, Use With Other Acetaminophen-containing Products </a></span>and<span class="Bold"><a href="#roo"> Risk of Overdosage</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.2"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of ULTRACET<span class="Sup">®</span> has not been studied in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="geriatric"></a><a name="section-7.3"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function; of concomitant disease; and multiple drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Acute Abdominal Conditions</h2>
<p class="First">The administration of ULTRACET<span class="Sup">®</span> may complicate the clinical assessment of patients with acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Use in <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">ULTRACET<span class="Sup">®</span> has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Experience with tramadol suggests that <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, it is recommended that the dosing interval of ULTRACET<span class="Sup">®</span> be increased, not to exceed 2 tablets every 12 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h2>
<p class="First">ULTRACET<span class="Sup">®</span> has not been studied in patients with impaired hepatic function. The use of ULTRACET<span class="Sup">®</span> in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not recommended (see<span class="Bold"><a href="#uwa"> WARNINGS, Use With Alcohol</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.7"></a><p></p>
<h2>Information for Patients</h2>
<ul class="Disc">
<li>Do not take ULTRACET<span class="Sup">®</span> if you are allergic to any of its ingredients.</li>
<li>If you develop signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, stop taking ULTRACET<span class="Sup">®</span> and contact your healthcare provider immediately.</li>
<li>Do not take more than 4,000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.</li>
<li>Do not take ULTRACET<span class="Sup">®</span> in combination with other tramadol or acetaminophen-containing products, including over-the-counter preparations.</li>
<li>ULTRACET<span class="Sup">®</span> may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and/or <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with concomitant use of serotonergic agents (including SSRIs, SNRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol.</li>
<li>ULTRACET<span class="Sup">®</span> may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.</li>
<li>ULTRACET<span class="Sup">®</span> should not be taken concomitantly with alcohol-containing beverages during the course of treatment with ULTRACET<span class="Sup">®</span>.</li>
<li>ULTRACET<span class="Sup">®</span> should be used with caution when taking medications such as tranquilizers, hypnotics, or other opiate-containing analgesics.</li>
<li>Inform the physician if you are pregnant, think you might become pregnant, or are trying to become pregnant (see<span class="Bold"><a href="#LAD"> PRECAUTIONS, Labor and Delivery</a></span>).</li>
<li>Understand the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, hepatic toxicity, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.8"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.1"></a><p></p>
<h3>CYP2D6 and CYP3A4 Inhibitors</h3>
<p class="First">Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see<span class="Bold"><a href="#pharmacokinetics"> CLINICAL PHARMACOLOGY, Pharmacokinetics</a></span>), such as quinidine, fluoxetine, paroxetine, and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol, increasing the risk for serious adverse events including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.2"></a><p></p>
<h3>Serotonergic Drugs</h3>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of tramadol and SSRIs/SNRIs or MAOIs and α2-adrenergic blockers. Caution is advised when ULTRACET<span class="Sup">®</span> is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, or St. John's Wort. If concomitant treatment of ULTRACET<span class="Sup">®</span> with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see<span class="Bold"><a href="#war_SS"> WARNINGS, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.3"></a><p></p>
<h3>Triptans</h3>
<p class="First">Based on the mechanism of action of tramadol and the potential for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, caution is advised when ULTRACET<span class="Sup">®</span> is coadministered with a triptan. If concomitant treatment of ULTRACET<span class="Sup">®</span> with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see<span class="Bold"><a href="#war_SS"> WARNINGS, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.4"></a><p></p>
<h3>Use With Carbamazepine</h3>
<p class="First">Patients taking<span class="Bold"> carbamazepine </span>may have a significantly reduced <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of tramadol. Because carbamazepine increases tramadol metabolism and because of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk associated with tramadol, concomitant administration of ULTRACET<span class="Sup">®</span> and carbamazepine is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.5"></a><p></p>
<h3>Use With Quinidine</h3>
<p class="First">Tramadol is metabolized to M1 by CYP2D6.<span class="Bold"> Quinidine </span>is a selective inhibitor of that isoenzyme; so that concomitant administration of quinidine and tramadol results in increased concentrations of tramadol and reduced concentrations of M1. The clinical consequences of these findings are unknown.<span class="Italics"> In vitro </span>drug interaction studies in human liver microsomes indicate that tramadol has no effect on quinidine metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.6"></a><p></p>
<h3>Potential for Other Drugs to Affect Tramadol</h3>
<p class="First"><span class="Italics">In vitro </span>drug interaction studies in human liver microsomes indicate that concomitant administration with inhibitors of CYP2D6 such as fluoxetine, paroxetine, and amitriptyline could result in some inhibition of the metabolism of tramadol. Administration of CYP3A4 inhibitors, such as ketoconazole and erythromycin, or inducers, such as rifampin and St. John's Wort, with ULTRACET<span class="Sup">®</span> may affect the metabolism of tramadol, leading to altered tramadol exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.7"></a><p></p>
<h3>Potential for Tramadol to Affect Other Drugs</h3>
<p class="First"><span class="Italics">In vitro </span>studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.8"></a><p></p>
<h3>Use With Cimetidine</h3>
<p class="First">Concomitant administration of ULTRACET<span class="Sup">®</span> and<span class="Bold"> cimetidine </span>has not been studied. Concomitant administration of tramadol and cimetidine does not result in clinically significant changes in tramadol pharmacokinetics. Therefore, no alteration of the ULTRACET<span class="Sup">®</span> dosage regimen is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.9"></a><p></p>
<h3>Use With Digoxin</h3>
<p class="First">Post-marketing surveillance of tramadol has revealed rare reports of<span class="Bold"> digoxin </span>toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8.10"></a><p></p>
<h3>Use With Warfarin-Like Compounds</h3>
<p class="First">Post-marketing surveillance of both tramadol and acetaminophen individual products have revealed rare alterations of warfarin effect, including elevation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times.</p>
<p>While such changes have been generally of limited clinical significance for the individual products, periodic evaluation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be performed when ULTRACET<span class="Sup">®</span> and warfarin-like compounds are administered concurrently.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There are no animal or laboratory studies on the combination product (tramadol and acetaminophen) to evaluate carcinogenesis, mutagenesis, or impairment of fertility.</p>
<p>A slight but statistically significant increase in two common murine tumors, pulmonary and hepatic, was observed in a mouse carcinogenicity study, particularly in aged mice. Mice were dosed orally up to 30 mg/kg (90 mg/m<span class="Sup">2</span> or 0.5 times the maximum daily human tramadol dosage of 185 mg/m<span class="Sup">2</span>) for approximately two years, although the study was not done with the Maximum Tolerated Dose. This finding is not believed to suggest risk in humans. No such finding occurred in a rat carcinogenicity study (dosing orally up to 30 mg/kg, 180 mg/m<span class="Sup">2</span>, or 1 time the maximum daily human tramadol dosage).</p>
<p>Tramadol was not mutagenic in the following assays: Ames<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>microsomal activation test, CHO/HPRT mammalian cell assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay (in the absence of metabolic activation), dominant lethal mutation tests in mice, chromosome aberration test in Chinese hamsters, and bone marrow micronucleus tests in mice and Chinese hamsters. Weakly mutagenic results occurred in the presence of metabolic activation in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and micronucleus test in rats. Overall, the weight of evidence from these tests indicates that tramadol does not pose a genotoxic risk to humans.</p>
<p>No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg (350 mg/m<span class="Sup">2</span>) in male rats and 75 mg/kg (450 mg/m<span class="Sup">2</span>) in female rats. These dosages are 1.6 and 2.4 times the maximum daily human tramadol dosage of 185 mg/m<span class="Sup">2</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.10"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.10.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">No drug-related teratogenic effects were observed in the progeny of rats treated orally with tramadol and acetaminophen. The tramadol/acetaminophen combination product was shown to be embryotoxic and fetotoxic in rats at a maternally toxic dose, 50/434 mg/kg tramadol/acetaminophen (300/2604 mg/m<span class="Sup">2</span> or 1.6 times the maximum daily human tramadol/acetaminophen dosage of 185/1591 mg/m<span class="Sup">2</span>), but was not teratogenic at this dose level. Embryo and fetal toxicity consisted of decreased fetal weights and increased supernumerary ribs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.10.2"></a><p></p>
<h3>Non-teratogenic Effects</h3>
<p class="First">Tramadol alone was evaluated in peri- and post-natal studies in rats. Progeny of dams receiving oral (gavage) dose levels of 50 mg/kg (300 mg/m<span class="Sup">2</span> or 1.6 times the maximum daily human tramadol dosage) or greater had decreased weights, and pup survival was decreased early in lactation at 80 mg/kg (480 mg/m<span class="Sup">2</span> or 2.6 times the maximum daily human tramadol dosage).</p>
<p>There are no adequate and well-controlled studies in pregnant women. ULTRACET<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. <span class="product-label-link" type="condition" conceptid="380533" conceptname="Convulsions in the newborn">Neonatal seizures</span>, neonatal withdrawal syndrome, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> have been reported with tramadol hydrochloride during post-marketing.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LAD"></a><a name="section-7.11"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">ULTRACET<span class="Sup">®</span> should not be used in pregnant women prior to or during labor unless the potential benefits outweigh the risks. Safe use in pregnancy has not been established. Chronic use during pregnancy may lead to physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and post-partum withdrawal symptoms in the newborn (see<span class="Bold"><a href="#DAAD"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>). Tramadol has been shown to cross the placenta. The mean ratio of serum tramadol in the umbilical veins compared to maternal veins was 0.83 for 40 women given tramadol during labor.</p>
<p>The effect of ULTRACET<span class="Sup">®</span>, if any, on the later growth, development, and functional maturation of the child is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.12"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">ULTRACET<span class="Sup">®</span> is not recommended for obstetrical preoperative medication or for post-delivery <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> in nursing mothers because its safety in infants and newborns has not been studied.</p>
<p>Following a single IV 100 mg dose of tramadol, the cumulative excretion in breast milk within 16 hours post-dose was 100 µg of tramadol (0.1% of the maternal dose) and 27 µg of M1.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Table 2 reports the incidence rate of treatment-emergent adverse events over five days of ULTRACET<span class="Sup">®</span> use in clinical trials (subjects took an average of at least 6 tablets per day).</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Incidence of Treatment-Emergent Adverse Events (≥2.0%)</span></caption>
<col align="left" valign="top" width="70%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th align="left">Body System<br>  Preferred Term</th>
<th align="center">ULTRACET<span class="Sup">®</span> (N=142)<br>(%)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Number of males = 62</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Gastrointestinal System Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Central &amp; Peripheral Nervous System</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Appendages</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span></td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Reproductive Disorders, Male <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="196734" conceptname="Disorder of prostate">Prostatic Disorder</span></td>
<td align="center">2</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Incidence at least 1%, causal relationship at least possible or greater</span>: the following lists adverse reactions that occurred with an incidence of at least 1% in single-dose or repeated-dose clinical trials of ULTRACET<span class="Sup">®</span>.</p>
<p><span class="Bold">Body as a Whole – </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span></p>
<p><span class="Bold">Central and Peripheral Nervous System – </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Bold">Gastrointestinal System – </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold">Psychiatric Disorders – </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold">Skin and Appendages – </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></p>
<p><span class="Italics">Selected Adverse events occurring at less than 1%</span>: the following lists clinically relevant adverse reactions that occurred with an incidence of less than 1% in ULTRACET<span class="Sup">®</span> clinical trials.</p>
<p><span class="Bold">Body as a Whole – </span><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, withdrawal syndrome</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> – </span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, aggravated <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p><span class="Bold">Central and Peripheral Nervous System – </span><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, aggravated <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold">Gastrointestinal System – </span><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span></p>
<p><span class="Bold">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span> – </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p>
<p><span class="Bold">Heart Rate and Rhythm Disorders – </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold">Liver and Biliary System – </span><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Hepatic function abnormal</span></p>
<p><span class="Bold">Metabolic and Nutritional Disorders – </span><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></p>
<p><span class="Bold">Psychiatric Disorders – </span><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, drug abuse, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">paroniria</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span></p>
<p><span class="Bold">Red Blood Cell Disorders – </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p>
<p><span class="Bold">Respiratory System – </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
<p><span class="Bold">Urinary System – </span><span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, micturition disorder, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
<p><span class="Bold">Vision Disorders – </span><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></p>
<p><span class="Italics">Post-marketing experience:</span> The following adverse reactions, not noted above, have been identified during post approval use of tramadol-containing products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span> –</span> <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span> – </span> <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, speech disorder</p>
<p><span class="Bold">Psychiatric disorders – </span><span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span></p>
<p><span class="Italics">Other clinically significant adverse experiences previously reported with tramadol hydrochloride</span>:</p>
<p>Other events which have been reported with the use of tramadol products and for which a causal association has not been determined include: vasodilation, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>/TENS), cognitive dysfunction, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal tendency</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Reported laboratory abnormalities included elevated creatinine and liver function tests. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> (whose symptoms may include mental status change, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>) has been reported with tramadol when used concomitantly with other serotonergic agents such as SSRIs and MAOIs. Cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have been reported very rarely in patients taking tramadol. Most reports were in patients with predisposing risk factors, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or in elderly patients.</p>
<p><span class="Italics">Other clinically significant adverse experiences previously reported with acetaminophen</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) or reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> secondary to acetaminophen are rare and generally controlled by discontinuation of the drug and, when necessary, symptomatic treatment.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="DAAD"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">ULTRACET<span class="Sup">®</span> (tramadol hydrochloride/acetaminophen) Tablets are classified as a Schedule IV controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-9.2"></a><p></p>
<h2>Abuse</h2>
<p class="First"><span class="Bold">Tramadol has mu-opioid agonist activity. ULTRACET<span class="Sup">®</span>, a tramadol-containing product, can be abused and may be subject to criminal diversion.</span></p>
<p>Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, use for non-medical purposes, continued use despite harm or risk of harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.</p>
<p>"Drug-seeking" behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated "loss" of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor shopping" to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of ULTRACET<span class="Sup">®</span> can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances.</p>
<p>Concerns about abuse and addiction should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.</p>
<p>Proper assessment of the patient and periodic re-evaluation of therapy are appropriate measures that help to limit the potential abuse of this product.</p>
<p>ULTRACET<span class="Sup">®</span> is intended for oral use only.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="section-9.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of drugs to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist (see also<span class="Bold"><a href="#war_withdrawal"> WARNINGS, Withdrawal</a></span>)<span class="Bold">.</span></p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate.</p>
<p><span class="Bold">Generally, tolerance and/or withdrawal are more likely to occur the longer a patient is on continuous therapy with ULTRACET<span class="Sup">®</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OD"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">ULTRACET<span class="Sup">®</span> is a combination product. The clinical presentation of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include the signs and symptoms of tramadol toxicity, acetaminophen toxicity or both. The initial symptoms of tramadol overdosage may include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The initial symptoms seen within the first 24 hours following an acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>. An overdosage of ULTRACET<span class="Sup">®</span> may be a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Tramadol</h2>
<p class="First">Acute overdosage with tramadol can be manifested by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been reported with abuse and misuse of tramadol (see<span class="Bold"><a href="#war_maad"> WARNINGS, Misuse, Abuse, and Diversion</a></span>). Review of case reports has indicated that the risk of fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids.</p>
<p>In the treatment of tramadol overdosage, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is also increased with naloxone administration. In animals, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> following the administration of toxic doses of ULTRACET<span class="Sup">®</span> could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in mice. Hemodialysis is not expected to be helpful in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> because it removes less than 7% of the administered dose in a 4-hour dialysis period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Acetaminophen</h2>
<p class="First">In<span class="Bold Italics"> acetaminophen </span>overdosage, dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and coagulation defects also may occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</p>
<p>In the treatment of acetaminophen overdosage, gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 or more hours after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected<span class="Bold Italics">.</span> Intravenous NAC may be administered when circumstances preclude oral administration.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose-dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DAA"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">For the short-term (five days or less) management of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>, the recommended dose of ULTRACET<span class="Sup">®</span> is 2 tablets every 4 to 6 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief, up to a maximum of 8 tablets per day.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Individualization of Dose</h2>
<p class="First">In patients with creatinine clearances of less than 30 mL/min, it is recommended that the dosing interval of ULTRACET<span class="Sup">®</span> be increased not to exceed 2 tablets every 12 hours. Dose selection for an elderly patient should be cautious, in view of the potential for greater sensitivity to adverse events.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ULTRACET<span class="Sup">®</span> (tramadol hydrochloride/acetaminophen) Tablets with tramadol 37.5 mg and acetaminophen 325 mg are light yellow, coated, capsule-shaped tablets imprinted "O-M" on one side and "650" on the other and are available as follows:</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="36%">
<tbody class="Headless">
<tr>
<td align="left">  100's:</td>
<td align="left">NDC 50458-650-60</td>
<td align="left">Bottles of 100 tablets</td>
</tr>
<tr>
<td align="left">  HUD 100's:</td>
<td align="left">NDC 50458-650-10</td>
<td align="left">Packages of 100 unit doses in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs, 10 cards of 10 tablets each </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Dispense in a tight container. Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, Puerto Rico 00778</p>
<p>Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, New Jersey 08560</p>
<p>© Janssen Pharmaceuticals, Inc. 2003<br>Revised July 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC 50458-650-60</span></p>
<p><span class="Bold Italics">ULTRACET</span><span class="Sup">®</span><span class="Bold"> CIV</span><br><span class="Italics">(37.5 mg tramadol <br>HCl/325 mg <br>acetaminophen <br>tablets)</span></p>
<p><span class="Underline">100 tablets</span><br><span class="Bold">Rx only.</span></p>
<p>janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d20df3c-8b5b-4bdf-a49f-ec904522575d&amp;name=ultracet-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRACET 		
					</strong><br><span class="contentTableReg">tramadol hydrochloride and acetaminophen tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-650</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tramadol hydrochloride</strong> (tramadol) </td>
<td class="formItem">tramadol hydrochloride</td>
<td class="formItem">37.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>acetaminophen</strong> (acetaminophen) </td>
<td class="formItem">acetaminophen</td>
<td class="formItem">325 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>powdered cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (light yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">O;M;650</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-650-60</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-650-10</td>
<td class="formItem">10  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021123</td>
<td class="formItem">08/15/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Janssen Pharmaceuticals, Inc.
							(063137772)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Ortho, LLC</td>
<td class="formItem"></td>
<td class="formItem">805887986</td>
<td class="formItem">MANUFACTURE(50458-650), ANALYSIS(50458-650)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mallinckrodt, Inc.</td>
<td class="formItem"></td>
<td class="formItem">097722284</td>
<td class="formItem">API MANUFACTURE(50458-650)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Proto Chemicals AG</td>
<td class="formItem"></td>
<td class="formItem">480008890</td>
<td class="formItem">API MANUFACTURE(50458-650)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>854c2053-daf5-44ff-a384-0b9c68b41cfe</div>
<div>Set id: 2d20df3c-8b5b-4bdf-a49f-ec904522575d</div>
<div>Version: 8</div>
<div>Effective Time: 20140728</div>
</div>
</div> <div class="DistributorName">Janssen Pharmaceuticals, Inc.</div></p>
</body></html>
